Video Experimental Relacionado

Updated: Sep 10, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Dirigirse a la senescencia celular mediada por p16^INK4a como estrategia terapéutica para la leucemia mieloide aguda

Jiarui Zheng^1,2, Linlin Jin^1,2, Yunlong Chen^1,2

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.

|August 21, 2025

Resumen

Las mutaciones FLT3-ITD en la leucemia mieloide aguda (LMA) suprimen el supresor tumoral p16INK4a, lo que lleva a la evasión de la senescencia y a peores resultados en los pacientes. Dirigirse a esta vía ofrece una nueva estrategia terapéutica para la LMA FLT3-ITD.

Área de la Ciencia:

En el campo de la oncología
Biología molecular
Genética del cáncer

Sus antecedentes:

La senescencia celular es un mecanismo supresor del tumor clave.
No se comprende bien el papel de la senescencia en la leucemia mieloide aguda (LMA) FLT3-ITD positiva.
Las mutaciones FLT3-ITD son comunes en la LMA y están asociadas con un mal pronóstico.

Objetivo del estudio:

Investigar el papel de p16INK4a en la LMA FLT3-ITD positiva.
Para aclarar los mecanismos moleculares por los cuales FLT3-ITD afecta la expresión de p16INK4a.
Identificar posibles objetivos terapéuticos para la LMA FLT3-ITD.

Principales métodos:

Análisis de múltiples conjuntos de datos de secuenciación de pacientes con LMA FLT3-ITD.
p16INK4a Modelos de ratón noqueado con LMA FLT3-ITD.
Investigación del eje de señalización STAT5A-E2F3-EZH2.

Principales resultados:

La baja expresión de p16INK4a en pacientes con LMA FLT3-ITD se correlaciona con pronósticos significativamente peores.
El KO de p16INK4a acelera el inicio de la LMA FLT3-ITD en ratones.
FLT3-ITD suprime p16INK4a a través de la vía STAT5A-E2F3-EZH2, promoviendo la evasión de la senescencia y la malignidad.
Un bucle de retroalimentación positiva exacerba la progresión de la enfermedad.

Conclusiones:

El eje FLT3-ITD-STAT5A/E2F3/EZH2-p16INK4a explica la baja supervivencia en un subconjunto de pacientes con LMA FLT3-ITD.
Este eje representa un objetivo terapéutico prometedor para la LMA FLT3-ITD refractaria con baja expresión de p16INK4a.

Más Videos Relacionados

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence

A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence

Published on: August 12, 2018

Videos de Conceptos Relacionados

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...